ASX-Dividend-Report-Banner

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

February 21, 2024 07:00 PM AEDT | By Cision
 Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro
Image source: Kalkine Media

PORTO, Portugal, Feb. 21, 2024 /PRNewswire/ -- A team of researchers from Germany, the USA, the UK, and Norway won the third edition of the BIAL Award in Biomedicine, a 300,000 Euro prize promoted by the BIAL Foundation, which seeks to recognise a work in biomedicine of exceptional quality and scientific relevance published in the last ten years.

Lead researchers of the winning team of the BIAL Award in Biomedicine 2023 promoted by the BIAL Foundation. Photo credits: Thomas Kuner - Hendrik Schröder, Heidelberg University Hospital; Frank Winkler - berlin-event-foto.de; Varun Venkataramani - Carina Kircher and Gerald Bendner.
Lead researchers of the winning team of the BIAL Award in Biomedicine 2023 promoted by the BIAL Foundation. Photo credits: Thomas Kuner - Hendrik Schröder, Heidelberg University Hospital; Frank Winkler - berlin-event-foto.de; Varun Venkataramani - Carina Kircher and Gerald Bendner.

Led by researchers Varun Venkataramani (first author), Frank Winkler, and Thomas Kuner (senior co-authors) from the University of Heidelberg in Germany, the study "Glutamatergic synaptic input to glioma cells drives brain tumour progression", published in Nature in 2019, represents breakthrough research important for understanding human cancer, specifically glioblastomas, a very aggressive type of brain tumour with an average survival time of just 1.5 years, even with state-of-the-art treatment.

In this work, the authors showed that glioblastomas and other incurable gliomas can integrate themselves into the function of the brain, and that input from healthy brain cells, normally used in functions such as thinking and memory, drives the progression of gliomas. This is possible by formation of synapses between neurons and cancer cells.

For the president of the Jury, "these findings are a major and surprising advance in the understanding of how brain cancer progresses, by describing a new communication channel between neurons and the tumour and by suggesting specific avenues for treatment".

This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues. "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.

The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

The winning paper, chosen from 70 nominations, is co-authored by 29 researchers from Heidelberg University, Heidelberg University Hospital, German Cancer Research Center, University Hospital Mannheim, Otto-von-Guericke University (Germany), Johns Hopkins University School of Medicine (USA), University of Glasgow (UK), University of Bergen, and Haukeland University Hospital (Norway).

It should be noted that two of the scientists who won the 2021 edition of this Award, Katalin Karikó, and Drew Weissman, were awarded the 2023 Nobel Prize in Physiology or Medicine for their discoveries that enabled the development of vaccines based on mRNA to prevent COVID-19.

 

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.